Featured Research

from universities, journals, and other organizations

Molecular mechanism contributing to cardiomyopathy elucidated

Date:
April 1, 2012
Source:
Helmholtz Association of German Research Centres
Summary:
Cardiomyopathy comprises a deterioration of the heart muscle that affects the organ's ability to efficiently pump blood through the body. Forms of the disease were tied to the alternative splicing of titin, a giant protein that determines the heart`s structure and biomechanical properties, but the molecular mechanism remained unknown. Scientists have now found that a gene tied to hereditary cardiomyopathy, regulates titin splicing. Their findings could lead to improve diagnosis and therapies.

Cardiomyopathy comprises a deterioration of the heart muscle that affects the organ's ability to efficiently pump blood through the body. Previously researchers have tied forms of the disease to the alternative splicing of titin, a giant protein that determines the structure and biomechanical properties of the heart, but the molecular mechanism remained unknown.

Professor Michael Gotthardt and Professor Norbert Hübner of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Germany, and colleagues have found that the RNA binding motif protein 20 (RBM20), a gene previously tied to hereditary cardiomyopathy, regulates titin splicing. Understanding this molecular mechanism behind heart function and failure, could lead to more efficient molecular diagnosis and therapies for this sometimes insidious disease.

The ventricular filling of the heart is regulated by the different protein isoforms of titin which are produced through alternative splicing, a process in which the protein-coding regions of RNA (the exons) are connected in different ways, resulting in multiple mRNAs (messenger RNAs) that give rise to many proteins.

Professor Marion Greaser of the University of Wisconsin-Madison, USA, had recently identified a naturally occurring rat strain deficient in titin splicing, which resulted in an elongated titin protein. "Titin naturally shortens around birth as the blood flow is redirected through the heart," Professor Gotthardt explained, "but these rats maintained the excessively long embryonic titin isoforms, which suggests a cause for their cardiomyopathy."

Using genome-wide mapping techniques, the researchers found a loss-of-function mutation in RBM20 in all the rats that expressed the pathological titin isoform. The rats with this mutation also shared many phenotypic similarities with human patients suffering from RBM20 related cardiomyopathy; specifically, ventricular enlargement, arrhythmia, increased rate of sudden death, and extensive fibrosis.

The researchers also identified a set of 31 genes shared by humans and rats that regulate splicing with RBM20. Included in this group was titin, thus validating the group's previous findings. Many of these genes have previously been tied to cardiomyopathy, ion-homeostasis, and sarcomere biology and future analysis will help resolve their individual contribution to the progression of the disease.

Towards utilizing these findings in a clinical setting, Professor Gotthardt has developed a technique to characterize the functional consequences of individual RBM20 mutations. "We can help patients learn if their RBM20 mutation will likely result in the severe form of the disease so that their physician can devise an appropriate therapy," added Professor Gotthardt. "We are currently utilizing this information to develop novel therapeutic strategies for patients suffering from severe forms of cardiomyopathy."


Story Source:

The above story is based on materials provided by Helmholtz Association of German Research Centres. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wei Guo, Sebastian Schafer, Marion L Greaser, Michael H Radke, Martin Liss, Thirupugal Govindarajan, Henrike Maatz, Herbert Schulz, Shijun Li, Amanda M Parrish, Vita Dauksaite, Padmanabhan Vakeel, Sabine Klaassen, Brenda Gerull, Ludwig Thierfelder, Vera Regitz-Zagrosek, Timothy A Hacker, Kurt W Saupe, G William Dec, Patrick T Ellinor, Calum A MacRae, Bastian Spallek, Robert Fischer, Andreas Perrot, Cemil Özcelik, Kathrin Saar, Norbert Hubner, Michael Gotthardt. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nature Medicine, 2012; DOI: 10.1038/nm.2693

Cite This Page:

Helmholtz Association of German Research Centres. "Molecular mechanism contributing to cardiomyopathy elucidated." ScienceDaily. ScienceDaily, 1 April 2012. <www.sciencedaily.com/releases/2012/04/120401135341.htm>.
Helmholtz Association of German Research Centres. (2012, April 1). Molecular mechanism contributing to cardiomyopathy elucidated. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/04/120401135341.htm
Helmholtz Association of German Research Centres. "Molecular mechanism contributing to cardiomyopathy elucidated." ScienceDaily. www.sciencedaily.com/releases/2012/04/120401135341.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins